Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.52 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.49 |
| ▸ | CASP1 | P29466 | 8/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.42 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.42 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.39 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14598390 | 1.00 | ANPEP (0.52) | ANPEPPSMB5CASP1CASP3CASP6 | |
| SCHEMBL5491095 | 0.87 | ANPEP (0.47) | ANPEPPSMB5CASP1CASP3CASP6 | |
| SCHEMBL14582929 | 0.86 | ANPEP (0.57) | ANPEPPSMB5CASP1CASP3CASP6 | |
| SCHEMBL5488547 | 0.85 | ANPEP (0.51) | ANPEPPSMB5CASP1MEN1MAPT | |
| SCHEMBL5488516 | 0.81 | CASP3 (0.55) | ANPEPPSMB5CASP1CASP3CASP6 | |
| SCHEMBL6830955 | 0.81 | CASP1 (0.59) | ANPEPPSMB5CASP1CASP3TDP1 | |
| SCHEMBL5490199 | 0.79 | CASP3 (0.59) | CASP1CASP3CASP6CASP8MEN1 | |
| SCHEMBL7672483 | 0.79 | ANPEP (0.48) | ANPEPPSMB5MEN1MAPTKMT2A | |
| SCHEMBL7625305 | 0.79 | ANPEP (0.48) | ANPEPPSMB5MEN1MAPTKMT2A | |
| SCHEMBL14598380 | 0.78 | CASP1 (0.60) | ANPEPPSMB5CASP1CASP3CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157430-B2 | (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20040259804-A1 | (Substituted)Acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. | 2004-12-23 | — | — | US | disclosed |
| US-20020091089-A1 | (Substituted)acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases | KARANEWSKY DONALD S (US) | 2002-07-11 | — | — | US | disclosed |
| US-6242422-B1 | (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases | IDUN PHARMACUETICALS, INC. | 2001-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091089-A1 | (Substituted)acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases | DPP3, IAPP, CASP3 | ANPEP 102/4885PSMB5 1184/4885CASP1 5/4885 |
| US-20040259804-A1 | (Substituted)Acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases | DPP3, IAPP, CASP3 | ANPEP 102/4885PSMB5 1184/4885CASP1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.